Ghost Tree Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ghost Tree Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-60,000	Closed	-$2.61M	–	87
2023 Q3	$2.61M	Sell	60,000 -140,000	-70%	-$5M	0.86%	41
2023 Q2	$7.23M	Buy	200,000 +60,000	+43%	+$2.47M	2.39%	16
2023 Q1	$5.21M	Sell	140,000 -60,000	-30%	-$2.7M	1.54%	27
2022 Q4	$9.06M	Buy	200,000 +25,000	+14%	+$1.62M	3.87%	11
2022 Q3	$12.2M	Buy	175,000 +65,000	+59%	+$4.81M	3.43%	10
2022 Q2	$7.38M	Buy	110,000 +90,000	+450%	+$5.72M	3.85%	9
2022 Q1	$1.64M	Sell	20,000 -10,000	-33%	-$1.02M	0.36%	37
2021 Q4	$4.4M	Sell	30,000 -30,000	-50%	-$4.66M	1.58%	25
2021 Q3	$10.6M	Buy	60,000 +10,000	+20%	+$1.61M	3.1%	10
2021 Q2	$8.08M	Hold	50,000	–	–	2.22%	14
2021 Q1	$8.56M	Hold	50,000	–	–	2.01%	17
2020 Q4	$11M	Sell	50,000 -10,000	-17%	-$2.16M	2.45%	18
2020 Q3	$9.96M	Sell	60,000 -95,000	-61%	-$13M	2.88%	9
2020 Q2	$17.7M	Buy	155,000 +40,000	+35%	+$3.88M	4.67%	6
2020 Q1	$8.84M	Sell	115,000 -35,000	-23%	-$3.14M	2.34%	15
2019 Q4	$19.3M	Sell	150,000 -125,000	-45%	-$12.1M	3.68%	6
2019 Q3	$21.4M	Sell	275,000 -60,000	-18%	-$5.63M	5.46%	4
2019 Q2	$34.5M	Buy	335,000 +185,000	+123%	+$14.4M	7.16%	5
2019 Q1	$11M	Sell	150,000 -250,000	-63%	-$17M	2.87%	13
2018 Q4	$17M	Sell	400,000 -35,300	-8%	-$1.41M	6.16%	2
2018 Q3	$20.5M	Sell	435,300 -64,700	-13%	-$3.6M	4.36%	4
2018 Q2	$24.6M	Buy	500,000 +237,500	+90%	+$8.97M	7.25%	2
2018 Q1	$8.06M	Sell	262,500 -337,500	-56%	-$9.37M	1.63%	19
2017 Q4	$10.9M	Buy	+600,000	New	+$9.31M	2.57%	12
2017 Q2	–	Sell	-172,184	Closed	-$895K	–	79
2017 Q1	$895K	Hold	172,184	–	–	0.17%	60
2016 Q4	$818K	Sell	172,184 -102,816	-37%	-$559K	0.2%	65
2016 Q3	$1.82M	Buy	275,000 +200,000	+267%	+$1.06M	0.29%	69
2016 Q2	$410K	Sell	75,000 -175,000	-70%	-$2.79M	0.12%	60
2016 Q1	$5.35M	Hold	250,000	–	–	3.03%	13
2015 Q4	$7.9M	Buy	+250,000	New	+$8.83M	3.23%	11

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Ghost Tree Capital's MRTX Position: Q4 2023 in Review

Ghost Tree Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 60,000 shares — an estimated $2.61M sold.

Ghost Tree Capital first reported a position in MRTX in Q4 2015 and held it in 30 quarters. The position peaked at $34.5M in Q2 2019. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Ghost Tree Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 60,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.61M.
Ghost Tree Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 30 quarters.
Ghost Tree Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $34.5M in Q2 2019.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.